HR5160-119

Reported

Stem Cell Therapeutic and Research Reauthorization Act of 2025

119th Congress Introduced Sep 4, 2025

Summary

What This Bill Does

This bill reauthorizes federal stem cell transplantation programs. It amends the Public Health Service Act authorization for the C.W. Bill Young Cell Transplantation Program by preserving the existing $31,009,000 amount and adding $33,009,000 for each of fiscal years 2027 through 2031. It also amends the Stem Cell Therapeutic and Research Act of 2005 so the national cord blood inventory authorization runs through 2031 instead of 2026.

Who Benefits and How

Patients needing bone marrow or cord blood transplants benefit because the national donor and cord blood infrastructure remains authorized for another five years. The C.W. Bill Young Cell Transplantation Program benefits from a specified $33,009,000 annual authorization for fiscal years 2027 through 2031. Cord blood banks benefit from continued federal support for inventory collection, maintenance, and access. Transplant centers and hematology clinicians benefit from more stable federal support for donor matching and graft availability. Biomedical researchers using cord blood and stem cell data benefit from continued program infrastructure.

Who Bears the Burden and How

Health Resources and Services Administration program staff must administer the reauthorized transplantation and cord blood inventory programs. Federal appropriators must decide whether to provide the authorized annual funding. Cord blood inventory administrators must continue meeting program standards, collection goals, and reporting requirements. Taxpayers bear the cost if Congress funds the authorization.

Key Provisions

  • Authorizes $33,009,000 for the C.W. Bill Young Cell Transplantation Program for each of fiscal years 2027 through 2031.
  • Preserves the existing $31,009,000 authorization language in section 379B.
  • Extends the national cord blood inventory authorization from 2026 to 2031.
  • Supports continued donor matching, cord blood inventory, and transplant access infrastructure.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

Reauthorizes the C.W. Bill Young Cell Transplantation Program at $33,009,000 for each of fiscal years 2027 through 2031 and extends the national cord blood inventory authorization from 2026 to 2031.

Key Policy Areas

Health Care, Biomedical Research, Transplantation

Primary Purpose

Reauthorizes the C.W. Bill Young Cell Transplantation Program at $33,009,000 for each of fiscal years 2027 through 2031 and extends the national cord blood inventory authorization from 2026 to 2031.

Policy Domains

Health Care Biomedical Research Transplantation

House resolution provisions

Identified Gains
  • Patients needing bone marrow transplants
  • Patients needing cord blood transplants
  • C.W. Bill Young Cell Transplantation Program staff
  • Cord blood banks
  • Transplant centers
  • Biomedical researchers
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
Cord blood banks:
Transplant centers:
Biomedical researchers:
Patients needing cord blood transplants:
Patients needing bone marrow transplants:
C.W. Bill Young Cell Transplantation Program staff:
Identified Costs
  • Health Resources and Services Administration program staff
  • Federal appropriators
  • Cord blood inventory administrators
  • Taxpayers
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: ih
Taxpayers:
Federal appropriators:
Cord blood inventory administrators:
Health Resources and Services Administration program staff:

Legislative Progress

Reported
Introduced Committee Passed
May 21, 2026

Ordered to be Reported (Amended) by the Yeas and Nays: …

May 21, 2026

Committee Consideration and Mark-up Session Held

May 13, 2026

Forwarded by Subcommittee to Full Committee by Voice Vote.

May 13, 2026

Subcommittee Consideration and Mark-up Session Held

Sep 4, 2025

Referred to the Subcommittee on Health.

Sep 4, 2025

Referred to the House Committee on Energy and Commerce.

Sep 4, 2025

Introduced in House

Sep 4, 2025

Mr. Smith of New Jersey (for himself, Ms. Matsui, Mr. …

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Healthcare
4 mentions across 1 clause
+4 positive

C.W. Bill Young Cell Transplantation Program staff, Cord blood banks, Patients needing bone marrow transplants

Government
2 mentions across 1 clause
-2 negative

Federal appropriators, HRSA program staff

1/3
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Health Care Biomedical Research Transplantation
Actor Mappings
"hrsa"
→ Health Resources and Services Administration

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology